Lupin’s stock rises in the wake of USFDA nod for Aurangabad facility
Shital Jibhe / 22 Aug 2017
With the news that Lupin has received the Establishment Inspection Report (EIR) from USFDA for its Aurangabad facility, the company’s stock picked up momentum and was trading at Rs 948.3, up by 2.76% on the BSE at 0916 hours.
With the news that Lupin, engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) across the world, has received the Establishment Inspection Report (EIR) from USFDA for its Aurangabad facility, the company’s stock picked up momentum and was trading at Rs 948.3, up by 2.76% on the BSE at 0916 hours.
The inspection was carried out in April 2017 and now stands closed.
The stock has adjusted 52-week high at Rs 1,590 (September 9, 2016) and adjusted 52-week low at Rs 920 (August 21, 2017) on the BSE. The share price of the company has witnessed turnover of Rs 2.14 crore with
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.